CABA
Cabaletta BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
CABA vs peer average
56/100
CABA vs. peer average (B vs. B)
Grade spread
A 5 · B 1 · C 1 · D 1 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
RNAC is the first available peer comparator.
Cartesian is a relevant adjacent peer because it is developing cell therapy for autoimmune disease across myasthenia gravis, SLE, and myositis, with an explicit outpatient and no-pretreatment-chemo positioning; the modality differs from Cabaletta's CD19 CAR-T, but it is a much closer operating comparator for autoimmune cell-therapy adoption and indication overlap.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CABA
Cabaletta Bio
RNAC
Cartesian Therapeutics
Grade
B
C
Momentum
89
56
Value
41
41
Sentiment
47
-
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs RNAC
CABA / RNAC
Grade Position
In line
CABA vs. peer average (B vs. B)
56/100
Momentum
89
CABAValue
41
CABASentiment
47
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CABA
RNAC is the first peer returned for this comparison set.